---
annotation-target: bloodadvances.2022007875.pdf
---


>%%
>```annotation-json
>{"created":"2022-08-30T03:51:35.470Z","text":"Small ubiquitin-like modifier（SUMO）是近年来被发现数种与ubiquitin相类似的蛋白质之一。它可经由类似ubiquitination的过程而与目标蛋白质上特定的赖氨酸支链形成共价键，而修饰目标蛋白质，这个过程称为SUMOylation。多种基因转录因子、讯息传递分子及病毒蛋白已被证实会被SUMO修饰；与ubiquitination不同的是，SUMOylation不会促进其目标蛋白质的降解。已知SUMOylation的功能包括：1.影响蛋白质间的交互作用。2.改变蛋白质于细胞内座落的位置。3.增加蛋白质的稳定性。在哺乳动物的系统中，有许多参与基因表现的蛋白质（包括transcriptional activators、repressors、coactivators与corepressors）被报导会被SUMO修饰；SUMO修饰上述蛋白质后，大多会抑制基因的转录。至于SUMO修饰究竟如何去抑制基因的转录，仍有待进一步的研究与厘清。","updated":"2022-08-30T03:51:35.470Z","document":{"title":"bloodadvances.2022007875.pdf","link":[{"href":"urn:x-pdf:c3c792ad9b2de5da3229179197239459"},{"href":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf"}],"documentFingerprint":"c3c792ad9b2de5da3229179197239459"},"uri":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf","selector":[{"type":"TextPositionSelector","start":144,"end":155},{"type":"TextQuoteSelector","exact":"SUMOylation","prefix":"0545bloodadvances@hematology.org","suffix":" inhibition overcomes proteasome"}]}]}
>```
>%%
>*%%PREFIX%%0545bloodadvances@hematology.org%%HIGHLIGHT%% ==SUMOylation== %%POSTFIX%%inhibition overcomes proteasome*
>%%LINK%%[[#^9mh391g6han|show annotation]]
>%%COMMENT%%
>Small ubiquitin-like modifier（SUMO）是近年来被发现数种与ubiquitin相类似的蛋白质之一。它可经由类似ubiquitination的过程而与目标蛋白质上特定的赖氨酸支链形成共价键，而修饰目标蛋白质，这个过程称为SUMOylation。多种基因转录因子、讯息传递分子及病毒蛋白已被证实会被SUMO修饰；与ubiquitination不同的是，SUMOylation不会促进其目标蛋白质的降解。已知SUMOylation的功能包括：1.影响蛋白质间的交互作用。2.改变蛋白质于细胞内座落的位置。3.增加蛋白质的稳定性。在哺乳动物的系统中，有许多参与基因表现的蛋白质（包括transcriptional activators、repressors、coactivators与corepressors）被报导会被SUMO修饰；SUMO修饰上述蛋白质后，大多会抑制基因的转录。至于SUMO修饰究竟如何去抑制基因的转录，仍有待进一步的研究与厘清。
>%%TAGS%%
>
^9mh391g6han


>%%
>```annotation-json
>{"created":"2022-08-30T05:38:48.695Z","updated":"2022-08-30T05:38:48.695Z","document":{"title":"bloodadvances.2022007875.pdf","link":[{"href":"urn:x-pdf:c3c792ad9b2de5da3229179197239459"},{"href":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf"}],"documentFingerprint":"c3c792ad9b2de5da3229179197239459"},"uri":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf","selector":[{"type":"TextPositionSelector","start":11009,"end":11314},{"type":"TextQuoteSelector","exact":"Genetic lesions that are associated with MM include the loss-of-function of tumor suppressors 70 and cell cycle regulators (p53, CDKN2C, RB) as well as the activation of oncogenic signaling  71 pathways (MYC, RAS, NFκB), leading to aberrant cell cycle checkpoint regulation and increased 72 proliferation ","prefix":" plasma-cell malignancy 1,2. 69 ","suffix":"3. Although the introduction of "}]}]}
>```
>%%
>*%%PREFIX%%plasma-cell malignancy 1,2. 69%%HIGHLIGHT%% ==Genetic lesions that are associated with MM include the loss-of-function of tumor suppressors 70 and cell cycle regulators (p53, CDKN2C, RB) as well as the activation of oncogenic signaling  71 pathways (MYC, RAS, NFκB), leading to aberrant cell cycle checkpoint regulation and increased 72 proliferation== %%POSTFIX%%3. Although the introduction of*
>%%LINK%%[[#^8murwdndh7f|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^8murwdndh7f


>%%
>```annotation-json
>{"created":"2022-08-30T05:39:22.819Z","updated":"2022-08-30T05:39:22.819Z","document":{"title":"bloodadvances.2022007875.pdf","link":[{"href":"urn:x-pdf:c3c792ad9b2de5da3229179197239459"},{"href":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf"}],"documentFingerprint":"c3c792ad9b2de5da3229179197239459"},"uri":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf","selector":[{"type":"TextPositionSelector","start":11442,"end":11905},{"type":"TextQuoteSelector","exact":"Currently, the common treatment regimens for MM 74 patients  include  proteasome  inhibitors  which  are  routinely  combined  with  dexamethasone, 75 chemotherapy,  immunomodulatory  drugs  (IMiDs)  or  CD38-specific  antibodies  5,6.  While  such 76 regimens can induce remissions for many years, the development of drug resistance remains a 77 major clinical problem 7,8. Therefore, new therapeutic strategies to overcome drug resistance are 78 urgently needed","prefix":"ients die from their disease 4. ","suffix":".  79 Post  translational  modif"}]}]}
>```
>%%
>*%%PREFIX%%ients die from their disease 4.%%HIGHLIGHT%% ==Currently, the common treatment regimens for MM 74 patients  include  proteasome  inhibitors  which  are  routinely  combined  with  dexamethasone, 75 chemotherapy,  immunomodulatory  drugs  (IMiDs)  or  CD38-specific  antibodies  5,6.  While  such 76 regimens can induce remissions for many years, the development of drug resistance remains a 77 major clinical problem 7,8. Therefore, new therapeutic strategies to overcome drug resistance are 78 urgently needed== %%POSTFIX%%.  79 Post  translational  modif*
>%%LINK%%[[#^mxisdjssvv|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^mxisdjssvv


>%%
>```annotation-json
>{"created":"2022-08-30T05:47:52.739Z","updated":"2022-08-30T05:47:52.739Z","document":{"title":"bloodadvances.2022007875.pdf","link":[{"href":"urn:x-pdf:c3c792ad9b2de5da3229179197239459"},{"href":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf"}],"documentFingerprint":"c3c792ad9b2de5da3229179197239459"},"uri":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf","selector":[{"type":"TextPositionSelector","start":12177,"end":12614},{"type":"TextQuoteSelector","exact":"imilar  to  ubiquitination,  protein 82 SUMOylation occurs via a tightly controlled enzymatic pathway controlled by a SUMO-specific 83 E1 activating enzyme (SAE1/UBA2), an E2 conjugating enzyme (UBE2I) and a subset of E3 84 SUMO ligases 10. Importantly, protein SUMOylation is fully reversible and executed by the SENP 85 (sentrin-specific  proteases)  family  of  isopeptidases,  making  SUMOylation  a  finely-tuned 86 molecular switch","prefix":"extra-cellular  signaling  9.  S","suffix":"  11,12. To date, only one heter"}]}]}
>```
>%%
>*%%PREFIX%%extra-cellular  signaling  9.  S%%HIGHLIGHT%% ==imilar  to  ubiquitination,  protein 82 SUMOylation occurs via a tightly controlled enzymatic pathway controlled by a SUMO-specific 83 E1 activating enzyme (SAE1/UBA2), an E2 conjugating enzyme (UBE2I) and a subset of E3 84 SUMO ligases 10. Importantly, protein SUMOylation is fully reversible and executed by the SENP 85 (sentrin-specific  proteases)  family  of  isopeptidases,  making  SUMOylation  a  finely-tuned 86 molecular switch== %%POSTFIX%%11,12. To date, only one heter*
>%%LINK%%[[#^ikrsg1dbyef|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^ikrsg1dbyef


>%%
>```annotation-json
>{"created":"2022-08-30T05:50:21.676Z","updated":"2022-08-30T05:50:21.676Z","document":{"title":"bloodadvances.2022007875.pdf","link":[{"href":"urn:x-pdf:c3c792ad9b2de5da3229179197239459"},{"href":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf"}],"documentFingerprint":"c3c792ad9b2de5da3229179197239459"},"uri":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf","selector":[{"type":"TextPositionSelector","start":13761,"end":14503},{"type":"TextQuoteSelector","exact":"To  date,  PIN1  is  the  only  known  peptidyl-prolyl  cis–trans  isomerase  that  can  specifically 97 recognize  and  isomerize  phosphorylated-Serine/phosphorylated-Threonine-Proline  motifs  and 98 thus change the stability of its target proteins 20. Dependent on the molecular context, PIN1 acts 99 either as an oncogene or a tumor suppressor 20. PIN1 modulates many target proteins and also 100 controls a variety of biological processes, including apoptosis 21. For example, PIN1 has been 101 shown to modulate p53, which was required for activation of the proapoptotic protein BAX  22. 102 PIN1 itself is also subject to various post-translational modifications, and SUMOylation of PIN1 103 has been shown to impair its activity 23. ","prefix":"sactivation activity 18,19.  96 ","suffix":"    104 Due to the wide array of"}]}]}
>```
>%%
>*%%PREFIX%%sactivation activity 18,19.  96%%HIGHLIGHT%% ==To  date,  PIN1  is  the  only  known  peptidyl-prolyl  cis–trans  isomerase  that  can  specifically 97 recognize  and  isomerize  phosphorylated-Serine/phosphorylated-Threonine-Proline  motifs  and 98 thus change the stability of its target proteins 20. Dependent on the molecular context, PIN1 acts 99 either as an oncogene or a tumor suppressor 20. PIN1 modulates many target proteins and also 100 controls a variety of biological processes, including apoptosis 21. For example, PIN1 has been 101 shown to modulate p53, which was required for activation of the proapoptotic protein BAX  22. 102 PIN1 itself is also subject to various post-translational modifications, and SUMOylation of PIN1 103 has been shown to impair its activity 23.== %%POSTFIX%%104 Due to the wide array of*
>%%LINK%%[[#^jabamty8rbk|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^jabamty8rbk


>%%
>```annotation-json
>{"created":"2022-08-30T05:52:00.728Z","updated":"2022-08-30T05:52:00.728Z","document":{"title":"bloodadvances.2022007875.pdf","link":[{"href":"urn:x-pdf:c3c792ad9b2de5da3229179197239459"},{"href":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf"}],"documentFingerprint":"c3c792ad9b2de5da3229179197239459"},"uri":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf","selector":[{"type":"TextPositionSelector","start":20151,"end":20228},{"type":"TextQuoteSelector","exact":"The SUMO pathway is activated in proteasome inhibitor-resistant MM cells 169 ","prefix":"mgartner et al.  8  RESULTS 168 ","suffix":"Dysregulation of the SUMO pathwa"}]}]}
>```
>%%
>*%%PREFIX%%mgartner et al.  8  RESULTS 168%%HIGHLIGHT%% ==The SUMO pathway is activated in proteasome inhibitor-resistant MM cells 169== %%POSTFIX%%Dysregulation of the SUMO pathwa*
>%%LINK%%[[#^boffmjjxyl8|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^boffmjjxyl8


>%%
>```annotation-json
>{"created":"2022-08-30T05:55:06.828Z","updated":"2022-08-30T05:55:06.828Z","document":{"title":"bloodadvances.2022007875.pdf","link":[{"href":"urn:x-pdf:c3c792ad9b2de5da3229179197239459"},{"href":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf"}],"documentFingerprint":"c3c792ad9b2de5da3229179197239459"},"uri":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf","selector":[{"type":"TextPositionSelector","start":35921,"end":36480},{"type":"TextQuoteSelector","exact":"Molecular homeostasis from apoptosis-associated proteins and its PTMs is critical for tumor cell 332 survival and therapy resistance. Despite a lack of p53 function, we observed p53 signatures in 333 all  cell  models  tested.  All  p53  family  members  (p53,  p63  and  p73)  are  able  to  bind  p53 334 consensus sequences to induce p53 target gene expression 40. TP53 mutations are seen in only 335 13% of MM patients, and are associated with worse overall survival  50. Activity of p53 family 336 proteins is regulated by different factors affecting PTM","prefix":"synergistic 330 lethality.  331 ","suffix":". The prolyl isomerase PIN1 has "}]}]}
>```
>%%
>*%%PREFIX%%synergistic 330 lethality.  331%%HIGHLIGHT%% ==Molecular homeostasis from apoptosis-associated proteins and its PTMs is critical for tumor cell 332 survival and therapy resistance. Despite a lack of p53 function, we observed p53 signatures in 333 all  cell  models  tested.  All  p53  family  members  (p53,  p63  and  p73)  are  able  to  bind  p53 334 consensus sequences to induce p53 target gene expression 40. TP53 mutations are seen in only 335 13% of MM patients, and are associated with worse overall survival  50. Activity of p53 family 336 proteins is regulated by different factors affecting PTM== %%POSTFIX%%. The prolyl isomerase PIN1 has*
>%%LINK%%[[#^5dw0lzjy4gq|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^5dw0lzjy4gq


>%%
>```annotation-json
>{"created":"2022-08-30T06:00:24.834Z","text":"Subasumstat (TAK-981)是一种新型的 SUMOylation enzymatic cascade 的选择性抑制剂，具有潜在的免疫激活和抗肿瘤活性","updated":"2022-08-30T06:00:24.834Z","document":{"title":"bloodadvances.2022007875.pdf","link":[{"href":"urn:x-pdf:c3c792ad9b2de5da3229179197239459"},{"href":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf"}],"documentFingerprint":"c3c792ad9b2de5da3229179197239459"},"uri":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/bloodadvances.2022007875.pdf","selector":[{"type":"TextPositionSelector","start":40575,"end":41069},{"type":"TextQuoteSelector","exact":"In  summary,  we  find  that  combination  of  the  SUMO  inhibitor  subasumstat  and  proteasome 375 inhibitors  acts  synergistically  in  MM  models  by  interfering  with  the  cellular  stress  response, 376 which  ultimately  triggers  intrinsic  tumor  cell  death.  A  combination  of  classical  proteasome 377 inhibitor-containing  regimens  with  inhibition  of  the  SUMO  pathway  could  be  a  promising 378 approach to address the frequently emerging therapy resistance in MM.  3","prefix":"Heynen, Baumgartner et al.  16  ","suffix":"79 AUTHOR CONTRIBUTIONS 380 Conc"}]}]}
>```
>%%
>*%%PREFIX%%Heynen, Baumgartner et al.  16%%HIGHLIGHT%% ==In  summary,  we  find  that  combination  of  the  SUMO  inhibitor  subasumstat  and  proteasome 375 inhibitors  acts  synergistically  in  MM  models  by  interfering  with  the  cellular  stress  response, 376 which  ultimately  triggers  intrinsic  tumor  cell  death.  A  combination  of  classical  proteasome 377 inhibitor-containing  regimens  with  inhibition  of  the  SUMO  pathway  could  be  a  promising 378 approach to address the frequently emerging therapy resistance in MM.  3== %%POSTFIX%%79 AUTHOR CONTRIBUTIONS 380 Conc*
>%%LINK%%[[#^p44nyl97b9q|show annotation]]
>%%COMMENT%%
>Subasumstat (TAK-981)是一种新型的 SUMOylation enzymatic cascade 的选择性抑制剂，具有潜在的免疫激活和抗肿瘤活性
>%%TAGS%%
>
^p44nyl97b9q
